Essity

Q1 2025: Managing Cost Headwinds with Strategic Resilience

27/04/25 -"Essity reported a 2.1% organic sales growth in Q1 2025, driven by pricing initiatives with stable volumes. Adjusted EBITA decreased by 3.5%. Although revenue and earnings fell short of consensus ..."

PDF page sample
Pages
53
Language
English
Published on
27/04/25
Download
You may also be interested by these reports :
30/04/25
Haleon’s Q1 organic sales largely aligned with market expectations, showing growth across all segments. Management reaffirmed its 2025 targets. ...
29/04/25
Puig reported an encouraging start to the year, outperforming the global beauty market. The ongoing softness in the premium makeup segment was fully ...
29/04/25
Essity (Add; Sweden), an attractive Health and Hygiene play, has further sharpened its ‘Health’ focus in recent years, resulting in reduced ...
27/04/25
Essity reported a 2.1% organic sales growth in Q1 2025, driven by pricing initiatives with stable volumes. Adjusted EBITA decreased by 3.5%. Although ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO